Sage nix­es pro­gram for Parkin­son’s dis­ease af­ter Phase 2 fail­ure

Sage Ther­a­peu­tics is ter­mi­nat­ing the de­vel­op­ment of its drug dalzanem­dor in Parkin­son’s dis­ease af­ter a mid-stage test end­ed in dis­ap­point­ment.

The Phase 2 PRECE­DENT tri­al com­pared the drug with place­bo in 86 Parkin­son’s pa­tients with mild cog­ni­tive im­pair­ment. It missed its pri­ma­ry end­point, fail­ing to show a sta­tis­ti­cal­ly sig­nif­i­cant dif­fer­ence in the Wech­sler Adult In­tel­li­gence Scale Fourth Edi­tion-IV Cod­ing Test score at 42 days ver­sus place­bo, ac­cord­ing to a Wednes­day re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER